Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues

Area of Science:

• Endocrinology and Metabolism
• Molecular Biology
• Pharmacology

Background:

• Fibroblast growth factor 21 (FGF21) is a key hepatokine regulating metabolic processes.
• FGF21 influences glucose and lipid metabolism, body weight, and insulin sensitivity.
• Pre-clinical and clinical studies highlight FGF21's therapeutic potential for metabolic diseases.

Purpose of the Study:

• To review the tissue-specific actions and molecular mechanisms of FGF21.
• To analyze the outcomes of clinical trials involving FGF21.
• To elucidate the complex physiology of FGF21 in metabolic regulation.

Main Methods:

• Literature review of pre-clinical and clinical studies on FGF21.
• Analysis of FGF21's roles in the liver, adipose tissue, and nervous system.
• Synthesis of data on FGF21's molecular mechanisms and clinical trial results.

Main Results:

• FGF21 demonstrates significant effects on glucose and lipid metabolism.
• FGF21 administration leads to reduced body weight and improved insulin sensitivity.
• Clinical trials provide insights into FGF21's efficacy and safety profile.

Conclusions:

• FGF21 is a promising therapeutic target for obesity and type 2 diabetes mellitus.
• Understanding FGF21's tissue-specific actions is crucial for its clinical application.
• Further research is warranted to fully delineate FGF21's physiological complexity and therapeutic utility.